BAM
BDTX icon

Belpointe Asset Management’s Black Diamond Therapeutics BDTX Stock Holding History

Belpointe Asset Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,201
Closed -$2.16K – 3736
2022
Q4 		$2.16K Buy
+1,201
New +$2.16K ﹤0.01% 3231

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Belpointe Asset Management's BDTX Position: Q1 2023 in Review

Belpointe Asset Management sold out of Black Diamond Therapeutics (BDTX) in Q1 2023, closing a stake of 1,201 shares — an estimated $2.16K sold.

Belpointe Asset Management first reported a position in BDTX in Q4 2022 and held it in 1 quarter. The position peaked at $2.16K in Q4 2022. 50 funds tracked by Wall St. Rank hold BDTX as of Q1 2023.

  • Belpointe Asset Management reported no remaining Black Diamond Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 1,201 Black Diamond Therapeutics shares in Q1 2023, an estimated $2.16K.
  • Belpointe Asset Management first reported a position in Black Diamond Therapeutics in Q4 2022 and held it in 1 quarter.
  • Belpointe Asset Management's Black Diamond Therapeutics position peaked at $2.16K in Q4 2022.
  • 50 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2023.

Based on Belpointe Asset Management's 13F filing for Q1 2023, filed 15 May 2023.